Search results for "hormonal refractory"

showing 1 items of 1 documents

Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Ef…

2021

Objective Eribulin mesylate (EM) is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin. EM has been reported to be active in metastatic breast cancer. In this paper, we report efficacy and safety of data of EM in a retrospective, real-world series of patients with poor prognosis, hormone-refractory, or triple-negative metastatic breast cancer. Materials and methods The analysis was carried out at 4 interrelated oncology centers. EM was delivered at the dose of 1.4 mg/m2 in 100 mL of normal saline over 2 to 5 minutes on days 1 and 8 every 21 days. EM was continued until disease progression or unacceptable toxicity. Side effects were reported every cycle …

Eribulin MesylateOncologyAdultCancer Researchmedicine.medical_specialtyNeoplasms Hormone-Dependenteribulin mesylateSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast Neoplasmstriple negative03 medical and health sciences0302 clinical medicineStable DiseaseBreast cancerbreast cancerInternal medicineAntineoplastic Combined Chemotherapy Protocolshormonal refractorymedicineHumans030212 general & internal medicineFuransSalineTriple-negative breast cancerAgedRetrospective StudiesChemotherapybusiness.industryKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerSettore MED/18 - Chirurgia GeneraleTreatment OutcomeOncology030220 oncology & carcinogenesisToxicityFemalebusiness
researchProduct